Revenue
2020
2021
2022
2023
2024
2025
ImageneBio, Inc. (IMA)
Price—Loading quote
Net income
2020
2021
2022
2023
2024
2025
Free cash flow
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $800,000 | $3.5M | $9.2M | $15.6M | $31.0M | $9.2M |
| Research & development | $28.5M | $32.1M | $59.7M | $64.3M | $47.1M | $44.8M |
| Operating expenses | $49.3M | $40.5M | $84.6M | $86.5M | $65.1M | $53.7M |
| Operating income | −$48.5M | −$37.0M | −$75.4M | −$70.9M | −$34.1M | −$44.5M |
| EBITDAderived | −$48.1M | −$35.9M | — | — | — | — |
| Net income | −$45.3M | −$36.6M | −$68.2M | −$68.8M | −$34.1M | −$44.3M |
| Basic EPSper diluted share | -$9.64 | -$22.10 | -$1.63 | -$1.90 | -$1.22 | -$16.00 |
| Diluted EPSper diluted share | -$9.64 | -$22.10 | -$1.63 | -$1.90 | -$1.22 | -$16.00 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 14, 2026Form 4 | Bonita David PDirector | BuyPre-Funded Warrants (right to buy) · derivative · indirect | 384.7K | — | — | 384.7K |
| Apr 14, 2026Form 4 | Bonita David PDirector | BuyPre-Funded Warrants (right to buy) · derivative · indirect | 336.6K | — | — | 336.6K |
| Apr 14, 2026Form 4 | OrbiMed Genesis GP LLC +2Director | BuyPre-Funded Warrants (right to buy) · derivative · indirect | 384.7K | — | — | 384.7K |
| Apr 14, 2026Form 4 | OrbiMed Genesis GP LLC +2Director | BuyPre-Funded Warrants (right to buy) · derivative · indirect | 336.6K | — | — | 336.6K |
| Dec 24, 2025Form 4 | SLATTERY JOSEPH PDirector | BuyCommon Stock | 16.0K | $5.99 | $95.8K | 16.0K |